Treatment strategies that com­bine Revlimid with newer types of anti-tumor agents may be ef­fec­tive for re­lapsed and re­frac­tory mul­ti­ple myeloma, ac­cord­ing to myeloma experts who reviewed re­­sults from stud­ies of these new com­bi­na­tions.

Refractory and re­lapsed mul­ti­ple myeloma is notoriously dif­fi­cult to treat. For every remission period that is achieved, relapse typ­i­cally arises sooner and with greater re­sis­tance to pre­vi­ously used ther­a­pies. These patients have lim­ited op­tions for ther­apy.

In examining trials that tested new ther­a­pies in com­bi­na­tion with Revlimid (lena­lido­mide), the authors of the review hoped to find the po­ten­tial …

Compound in Development for Multiple Myeloma

Horsham, PA (Press Release) – Janssen Biotech, Inc. ("Janssen"), one of the Janssen Pharma­ceu­tical Com­panies of Johnson & Johnson, announced today that it has executed a global license and devel­op­ment agree­ment with the Danish com­pany Genmab A/S for the anti-cancer com­­pound, dara­tu­mu­mab. Dara­tu­mu­mab (HuMax®-CD38) is a human CD38 mono­clonal anti­body cur­rently in Phase I/II studies in re­lapsed, refractory multiple myeloma.

"Janssen was one of the first com­pa­nies to recog­nize the power and promise of mono­clonal anti­bodies and today is a world leader in biologics. We look for­ward to applying that same …